By a News Reporter-Staff News Editor at Politics& Government Week A patent application by the inventor Ratnakar, Nitesh, filed on July 22, 2014, was made available online on November 13, 2014, according to news reporting originating from Washington, D.C., by VerticalNews correspondents. This patent application has not been assigned to a company o
By a News Reporter-Staff News Editor at Computer Weekly News ARUP Laboratories and PierianDx announced a partnership that will result in faster and more efficient diagnostic genetic testing for thousands of patients across the U.S. ARUP Laboratories, a leading national reference lab serving many of the nation's top university teaching hospitals,.
Cape Cod Healthcare executives said the organization has more recently sustained the business by growing outpatient services, but that the health system is well configured to adapt to health care's changing tides. Executives say a growth of outpatient services coupled with the business's diversification has helped Cape Cod Healthcare end the year w
The health insurance system in Egypt could easily be called a failure, as Egypt's Health Insurance Organization is subject to outdated laws that have scarcely been modified in line with skyrocketing costs across all sectors. Public hospitals have become a place to humiliate people who aren't privately insured. Dr. Gamal el-Zeiny, a former member of
Hovione announced today it has filed its first Investigational New Drug Application with the U.S. Food and Drug Administration. This event represents a milestone in Hovione's strategy of developing improved drug delivery options for established drugs. The IND was submitted for minocycline gel, a novel formulation using a new patented crystalline ba
Release date- 25112014- RARITAN, NJ, November 24, 2014- Janssen Research& Development, LLC has submitted a New Drug Application for YONDELIS to the U.S. Food and Drug Administration for the treatment of patients with advanced soft tissue sarcoma, including liposarcoma and leiomyosarcoma subtypes, who have received prior chemotherapy including an...
LifeTech Scientific Corporation said it. has recently obtained the final approval from the Center for Medical Device Evaluation of. the China Food and Drug Administration and its iron-based bioresorbable drug-eluting.
By a News Reporter-Staff News Editor at Politics& Government Week Dartmouth researchers say lung cancer screening in the National Lung Screening Trial meets a commonly accepted standard for cost effectiveness as reported in the Nov. 6 issue of the New England Journal of Medicine. "The takeaway from this study is that there is potential for lung
AstraZeneca accessed guidance and advice from MHRA to help them successfully navigate regulatory and scientific requirements in the development of their essential new facility in Macclesfield. This helped them develop the site quickly, cost effectively and ensured the production of vital cancer medicine here in the UK. John Parker, UK Quality Direc
The NDA for LBH589 was submitted to the FDA in March 2014. In May 2014, the FDA granted priority review status to LBH589, reducing the standard 12- month review period to eight months. 'We are committed to working with the FDA as they continue to review the LBH589 NDA,' said Alessandro Riva, MD, Global Head of Oncology Development and Medical Affai
According to a new market report published by Persistence Market Research "Global Market Study on Cranio Maxillofacial Implants: Asia to Witness Highest Growth by 2020" the global cranio maxillofacial implants market was valued at USD 1,044.7 million in 2014 and is expected to grow at a CAGR of 6.2% from 2014 to 2020, to reach an estimated value
SWOT, Economic and Business Environment specifics include:? Key strengths, weaknesses and threats influencing leading player position within the market? Top Five Contract Pharmaceutical Export Markets of China? Major players within China's leading therapeutic markets? Multinational penetration into the Chinese Pharma Market? Comprehensive
Revive Therapeutics Ltd. today announced its results for the three months ended September 30, 2014. Robert Terkeltaub, MD, as Principal Investigator for upcoming clinical trials of REV-002. On October 28, 2014, Revive applied to the FDA for orphan drug designation for REV-003. On October 30, 2014, Revive submitted an Investigational New Drug ap
Revive Therapeutics Ltd. is pleased to announce that the U.S. Food and Drug Administration has accepted the Company's Investigational New Drug Application to commence a clinical trial for REV-002 for the treatment of gout. FDA and its announcement that it has signed a material transfer agreement with a global pharmaceutical company headquartered in
Spain: PharmaMar announces that its partner Janssen has submitted a New Drug Application for YONDELIS to the U.S. In its press release, Janssen also announced plans to amend the protocol for the Phase III randomized, open-label study ET743-SAR-3007, on which the NDA submission is based. At the same time, Janssen will be revising the current U.S. tr
Spartan Bioscience today announced that it has received South Korean Ministry of Food and Drug Safety regulatory approval for its Spartan RX CYP2C19 System. Leading Korean institutions such as Chonnam National University Hospital, Chung-Ang University Hospital, and Konyang University College of Medicine are already using the Spartan RX CYP2C19 Syst
By a News Reporter-Staff News Editor at Politics& Government Week SQI Diagnostics Inc. announced that it has received notice that the United States Food and Drug Administration has cleared the Company to market its proprietary Celiac Panel in the United States. "We are very excited to have received FDA clearance," said Andrew Morris, CEO, SQI Di
The NDA for LBH589 was submitted to the FDA in March 2014. In May 2014, the FDA granted priority review status to LBH589, reducing the standard 12- month review period to eight months. "We are committed to working with the FDA as they continue to review the LBH589 NDA," said Alessandro Riva, MD, Global Head of Oncology Development and Medical Affa
Valeant Pharmaceuticals International has received approval from the Food and Drug Administration for ONEXTON Gel, 1.2%/ 3.75%, for the once-daily treatment of comedonal and inflammatory acne in patients 12 and older. We are very pleased that the FDA has approved this new dual action medication that gives physicians and patients a new option for th
The Association of the British Pharmaceutical Industry and the BioIndustry Association have welcomed the publication of the first case study showcasing the guidance MHRA can provide to pharmaceutical companies, looking to invest in the UK. This case study which was developed by MHRA with the support of the Medicines Manufacturing Industry Partnersh
Allegheny General Hospital, Allegheny Valley Hospital and West Penn Hospital, all part of the Allegheny Health Network, are among a select group of medical centers in the country, including just 57 in Pennsylvania, to be lauded as Top Performers on Key Quality Measures by The Joint Commission, the leading accreditor of health care organizations
Arch Biopartners Inc has now completed a Clinical Development Plan to prepare a human trial for MetaMx, the Company's brain tumour targeting technology. Arch Biopartners management intends to have these tasks completed in 2015.. A pre-Investigational New Drug meeting with the Food and Drug Administration is planned upon availability of toxicology d
In the Complete Response letter, and consistent with the preliminary feedback announced on November 7, 2014, the FDA requested that Avanir assess the root cause of device use errors observed in the previously conducted human factors testing. The FDA did not find any clinical or non-clinical safety or efficacy issues nor chemistry, manufacturing, an
Avaxia Biologics reported that the US Food and Drug Administration granted Orphan Drug Designation to AVX-470 for the treatment of pediatric ulcerative colitis. According to a company release, AVX-470 is a gut-targeted anti- TNF antibody, which earlier this year successfully completed a Phase 1 b clinical trial in adults with active ulcerative coli
Becton, Dickinson and Company is a global medical technology company engaged principally in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general...